HIKAL Intraday Analysis...

HIKAL Share Price

Open 205.90 Change Price %
High 210.95 1 Day 5.90 2.91
Low 202.05 1 Week 13.30 6.80
Close 208.90 1 Month -5.10 -2.38
Volume 107589 1 Year 86.20 70.25
52 Week High 256.80
52 Week Low 116.10
HIKAL Important Levels
Resistance 2 217.15
Resistance 1 213.75
Pivot 207.30
Support 1 204.05
Support 2 200.65
NSE INDIA Most Active Stocks
JPASSOCIAT 13.80 1.85%
SUZLON 18.25 -1.08%
UVSL 0.70 -6.67%
SBIN 288.45 2.25%
ASHOKLEY 84.00 -2.83%
IDEA 88.90 0.45%
BANKBARODA 173.50 -0.23%
UNITECH 5.45 -2.68%
ICICIBANK 282.20 1.88%
RCOM 38.15 -0.65%
More..
NSE INDIA Top Gainers Stocks
VKSPL 0.10 100.00%
AUSTRAL 0.30 20.00%
FCSSOFT 0.30 20.00%
UCALFUEL 218.70 20.00%
KOLTEPATIL 185.20 14.18%
DQE 21.60 12.79%
VSSL 134.20 12.44%
KANANIIND 17.05 11.44%
TRITURBINE 142.20 11.40%
SHALPAINTS 166.40 11.01%
More..
NSE INDIA Top Losers Stocks
HINDZINC 290.05 -11.03%
LAKSHMIEFL 60.30 -10.33%
NICCO 0.45 -10.00%
RESPONIND 86.75 -9.35%
FILATEX 114.25 -9.18%
KKCL 1643.00 -8.84%
GRAVITA 57.55 -8.43%
SKIL 20.25 -8.37%
GTNTEX 17.90 -8.21%
NTL 4.50 -8.16%
More..

Hikal Limited (NSE: HIKAL)

HIKAL Technical Analysis 1.5
As on 29th Mar 2017 HIKAL Share Price closed @ 208.90 and we RECOMMEND Buy for LONG-TERM with Stoploss of 193.54 & Sell for SHORT-TERM with Stoploss of 216.34 we also expect STOCK to react on Following IMPORTANT LEVELS.
HIKAL Target for March
1st Target up-side 230.05
2nd Target up-side 241.3
3rd Target up-side 252.55
1st Target down-side 197.95
2nd Target down-side 186.7
3rd Target down-side 175.45
HIKAL Synopsis Technicals View
50 Day EMA Close is Below EMA 50 (Short Term)
Bearish
100 Day EMA Close is Below EMA 100 (Mid Term) Bearish
200 Day EMA Close is Above EMA 200 (Long Term) Bullish
MACD (12 26 9) MACD Line is Grater Then SIGNAL Line Bullish
RSI (14) RSI is 55.06 Sideways
MFI (14) MFI is 57.32 Sideways
CCI (20) CCI is Above 100 Over Bought
WILLIAM %R (14) William %R is Above -20 Over Bought
ADX (14) ADX is Above 20 & +DI is Above -DI Up Trend
PSAR Stoploss For Long Buy 191.30
10 Day Avg Volume Traded 55.63 % More then 10 Day Average Volume
HIKAL Other Details
Segment EQ
Market Capital 0.00
Sector Basic Materials
Industry Chemicals - Major Diversified
Offical website http://www.hikal.com
HIKAL Address
HIKAL
717/718, Maker Chambers V
Nariman Point
Mumbai, 400021
India
HIKAL Latest News
Hikal Ltd opts for stock split   Hindu Business Line   - 17th Dec 14
Hikal board to decide on stock-split   Hindu Business Line   - 16th Dec 14
ICRA upgrades Credit Rating of Hikal Ltd   Equity Bulls   - 08th Aug 14
Upgradation in the Credit Rating   Hindu Business Line   - 07th Aug 14
Hikal gets FDA nod for Gujarat facility   Hindu Business Line   - 26th Apr 13
Hikal To Raise Debt From IFC   DealCurry   - 02nd Mar 13
Limited downside seen in Hikal, says Rajen Shah   Moneycontrol.com   - 18th May 12
Angel Broking bets on multibaggers Hikal and Finolex Cables   Moneycontrol.com   - 29th Dec 11
Hikal Limited   Moneycontrol.com   - 07th Dec 10
Hikal commissions new agro-chemical plant at Taloja   Economic Times   - 30th Jun 08
Interactive Technical Analysis Chart Hikal Limited ( HIKAL NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Hikal Limited
HIKAL Business Profile
Hikal (HIKAL), is in the business of providing a broad spectrum of R&D and custom manufacturing solutions to the pharmaceuticals, biotech, agrochemicals and specialty chemicals industries. The Company was incorporated on July 8, 1988. The company provides active ingredients, intermediates and R&D services and solutions. It supplies molecules for discovery research on a contract basis, develops non-infringing processes and scales them up to commercial scale production, undertakes method validation of new substances and custom manufacturing of key intermediates and active substances for pharmaceutical and agrochemical companies worldwide. The pharmaceutical intermediates are manufactured at Panoli, Gujarat and active ingredients are manufactured in Bangalore meeting regulated markets (US, Europe and Japan) standards. Commercialized APIs developed include Gabapentin, Ondansetron Hydrochloride, and Valproic acid; intermediates include Gabapentin Lactam, benzylchloride, among others. The company specializes in custom synthesis and contract manufacture of agrochemicals, intermediates and specialty chemicals by developing non-infringing processes for molecules and analytical development. Its Taloja, Panoli, and Mahad plants are ISO 17025, ISO 9000-2000, ISO 14001 and OHSAS18001 certified. Active ingredients include diuron and quinalphos; intermediates and specialty chemicals include 4-methyl thiazole, meta chloro aniline, among others. It also provides formulations including emulsifiable concentrates, wettable powders, suspension concentrates, and water dispersible granules. The company has long term agreements to supply the German company Degussa AG with pharmaceutical intermediates and active pharma ingredients (APIs) and the US-based Alpharma with active pharmaceutical ingredient (API) for the veterinary sector. The company operates mainly in India, United States, Canada, Europe, Africa South America, and South East Asia. It has investments in Jiangsu Chemstar Industries Co. and a shareholding of 16% in Chemstar Industries. The current market capitalization stands at Rs 780.90 crore. The company has reported a standalone sales of Rs 202.79 crore and a Net Profit of Rs 14.12 crore for the quarter ended September 2013. The company management includes Jai Hiremath - Chairman & Managing Director, Sameer Hiremath - Joint Managing Director, Baba Kalyani - Director, Prakash Mehta - Director, Shivkumar Kheny - Director, Kannan Unni - Director, Peter Pollak - Director, Amit Kalyani - Director, Wolfgang Welter - Director, Sugandha Hiremath - Director. The Registered office is at 717/718, Maker Chambers V, Nariman Point Mumbai, Maharashtra - 400021.